Gossamer Bio, Inc. (GOSS) News
Follow Gossamer Bio, Inc. (GOSS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split
Gossamer Bio regained compliance with Nasdaq's $1.00 minimum bid price requirement following a 1-for-80 reverse stock split.Key Highlights:Original SEC Filing: Gossamer Bio, Inc. [ GOSS ] - 8-K - Sep. 28, 2026This is an
REGULATION | Sep 28, 2026, 08:05 PM UTC
L
Gossamer Bio submits first NDA for seralutinib in pulmonary arterial hypertension
Gossamer Bio submitted a New Drug Application to the FDA for seralutinib for pulmonary arterial hypertension, its first NDA filing.Key Highlights:Original SEC Filing: Gossamer Bio, Inc. [ GOSS ] - 8-K - Sep. 23, 2026This
REGULATION | Sep 23, 2026, 08:15 PM UTC
L
Gossamer Bio, Inc. (GOSS) Files FDA NDA for Seralutinib in PAH
Gossamer Bio submitted a New Drug Application to the U.S. FDA for seralutinib to treat pulmonary arterial hypertension, supported by Phase 3 PROSERA and confirmatory Phase 2 TORREY data. FDA filing acceptance is pending
REGULATION | Sep 23, 2026, 08:02 PM UTC
L
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyperten
REGULATION | Sep 23, 2026, 08:01 PM UTC
L
GOSS: NDA filing for seralutinib is imminent, with strong clinical data and broad label prospects
The team is preparing an NDA for seralutinib following positive FDA feedback and strong phase III and subgroup data, especially in CTD-associated PAH. Broad label approval is anticipated, with rapid commercial uptake exp
REGULATION | Sep 09, 2026, 04:36 PM UTC
M
Seralutinib advances toward NDA filing as Gossamer Bio cites strong data
Gossamer Bio says positive FDA interactions and robust clinical data support an imminent NDA filing for seralutinib. The company highlights efficacy in key subgroups, a favorable safety profile, and a CTD-associated PAH
REGULATION | Sep 09, 2026, 03:54 PM UTC
L
Gossamer Bio announces 1-for-80 reverse stock split
Gossamer Bio announced a 1-for-80 reverse stock split.
EQUITY | Sep 09, 2026, 01:00 PM UTC
L
Gossamer Bio board approves amended bylaws effective Sept. 3
Gossamer Bio said its board approved amended bylaws effective Sept. 3, 2026. The company plans to present on seralutinib at the Cantor Global Healthcare Conference in New York on Sept. 9, 2026, with follow-up meetings pl
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
Gossamer Bio to present at Cantor Global Healthcare conference
Gossamer Bio, Inc. said it will present at the Cantor Global Healthcare Conference. The company is focused on seralutinib for pulmonary arterial hypertension (PAH) and PH-ILD.
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
Gossamer Bio board approves amended and restated bylaws effective Sept 3, 2026
Gossamer Bio, Inc. says its board approved an amendment and restatement of its bylaws, effective Sept 3, 2026.
REGULATION | Sep 03, 2026, 09:38 PM UTC
M
Gossamer Bio announces up to $250 million private placement
Gossamer Bio says it has entered a structured private placement for up to $250 million, including $150 million of committed capital, to fund seralutinib through potential FDA approval.
MNA | Aug 21, 2026, 12:01 PM UTC
M
Gossamer Bio announces up to $250M private placement for seralutinib
Gossamer Bio says it has entered a structured private placement for up to $250M, including $150M of committed capital, to fund seralutinib through potential FDA approval and operations into 2028.
MNA | Aug 21, 2026, 12:00 PM UTC
L
GOSS upgraded from Market Perform to Outperform W/ $1 PT @ Leerink
GOSS upgraded from Market Perform to Outperform W/ $1 PT @ Leerink
EQUITY | Jul 28, 2026, 11:24 AM UTC
L
GOSS u/g Outperform @ Leerink pt 100
GOSS u/g Outperform @ Leerink pt 100
EQUITY | Jul 28, 2026, 09:15 AM UTC
L
Top Small Cap Positive News Movers Premarket: LGHL: +120% Momentum Mover MTNB: +62% Sales Agreement Terminated DFNS: +59% SC 13D Filed BIYA
Top Small Cap Positive News Movers Premarket: LGHL: +120% Momentum Mover MTNB: +62% Sales Agreement Terminated DFNS: +59% SC 13D Filed BIYA: +44% Momentum Mover VTAK: +29% Partners with 319 Golf Society and Named Exclusi
EQUITY | Jul 27, 2026, 12:16 PM UTC